| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05213143 Details | 2024-04-19 Interventional | 4 | 13 | Lurasidone Hydr… Schizophrenia | Company's business decision - | |||
| NCT05040568 Details | 2024-04-19 Interventional | 1 | - | Cetuximab Cyclophosphamid… Fludarabine Fludarabine pho… Neoplasm, Resid… Colon Cancer Resected Stage | DMC Monitor Action - | |||
| NCT04949191 Details | 2024-04-19 Interventional | 2 | 10 | Pembrolizumab Neoplasms Advanced Malign… | A business decision due to availability of commercial drug and other options for accessing
study drug treatment. - | |||
| NCT04149574 Details | 2024-04-19 Interventional | 3 | 13 | BCG Vaccine Nivolumab Non-Muscle Inva… Urinary Bladder… | Insufficient enrollment, inability to meet protocol objectives, and slow accrual. - | |||
| NCT03801525 Details | 2024-04-19 Interventional | 2/3 | 277 | Venetoclax Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… Small Lymphocyt… | Strategic/Business decision Due to sponsor's business decision, the clinical trial was terminated by the sponsor prematurely. As such, the study results are reflective of the data captured to the time of study termination and with limited data verification. | |||
| NCT03186456 Details | 2024-04-19 Interventional | 1 | - | Aspirin Cerebral Infarc… Infarction | Others - | |||
| NCT03184935 Details | 2024-04-19 Interventional | 1/2 | - | Decitabine Myelodysplastic… Preleukemia Syndrome | Others - | |||
| NCT03176498 Details | 2024-04-19 Interventional | 1/2 | - | Aspirin Atorvastatin Calcium Cerebral Infarc… Infarction | Others - | |||
| NCT02875223 Details | 2024-04-19 Interventional | 1 | 75 | Itraconazole Pulrodemstat be… Rifampin Lymphoma Lymphoma, Non-H… Neoplasms | Business objectives have changed - | |||
| NCT05432804 Details | 2024-04-18 Interventional | 1/2 | - | Temozolomide Glioblastoma Recurrence MGMT-Methylated… Recurrent Gliob… Recurrent MGMT-… | End of Initial Phase of Multi-phase protocol - | |||
| NCT05264974 Details | 2024-04-18 Interventional | 1 | - | Vaccines Melanoma Recurrence | major protocol revision in progress - | |||
| NCT05177718 Details | 2024-04-18 Interventional | 4 | 1 | Natalizumab Multiple Sclero… Sclerosis | Sponsor declined further support - | |||
| NCT05104229 Details | 2024-04-18 Interventional | 3 | 0 | Aspirin Crohn Disease Thromboembolism Venous Thromboe… Ulcerative Coli… | Limited Resources - | |||
| NCT04546399 Details | 2024-04-18 Interventional | 2 | - | 2-Aminopurine Antibodies Antibodies, Bis… Antibodies, Mon… Antineoplastic … Asparaginase BB 1101 Blinatumomab Calcium Calcium, Dietar… Cyclophosphamid… Cytarabine Dexamethasone Dexamethasone a… Etoposide Etoposide phosp… Folic Acid Hydrocortisone Hydrocortisone … Hydrocortisone … Hydrocortisone … Immunoglobulins Leucovorin Levoleucovorin Mercaptopurine Methotrexate Muromonab-CD3 Nivolumab Pegaspargase Podophyllotoxin Thioguanine Vincristine Down Syndrome Leukemia Leukemia, Lymph… Precursor Cell … Recurrent B Acu… | Other - FDA Partial Clinical Hold - | |||
| NCT04145115 Details | 2024-04-18 Interventional | 2 | - | Ipilimumab Nivolumab Astrocytoma Glioblastoma Glioma Astrocytoma, ID… Diffuse Glioma Glioblastoma, I… Secondary Gliob… | Other - Evaluating accrual and study design - | |||
| NCT03435250 Details | 2024-04-18 Interventional | 1 | 123 | Docetaxel Gemcitabine Paclitaxel Lymphoma Advanced Solid … | Strategic reasons - | |||
| NCT03396471 Details | 2024-04-18 Interventional | 2 | 14 | Pembrolizumab Carcinoma Carcinoma, Unsp… | Study failed to meet its interim analysis endpoint - | |||
| NCT03311334 Details | 2024-04-18 Interventional | 1/2 | 47 | Nivolumab Pembrolizumab Carcinoma Carcinoma, Ovar… Carcinoma, Rena… Carcinoma, Tran… Fallopian Tube … Ovarian Neoplas… Fallopian Tube … Platinum-resist… Primary Periton… Renal Cell Carc… Serous Epitheli… Urothelial Carc… | Sponsor's decision to terminate development of the program. - | |||
| NCT03187080 Details | 2024-04-18 Interventional | 4 | - | Anesthetics Anesthetics, Lo… Bupivacaine Acute Pain Postoperative N… Vomiting Nausea Opioid Use Pain, Acute Satisfaction Vomiting, Posto… | per Research Hold - | |||
| NCT05581719 Details | 2024-04-17 Interventional | 1/2 | 14 | Nivolumab Tislelizumab Neoplasm Metast… Neoplasms Peritoneal Canc… Peritoneal Meta… Solid Tumor | Sponsor decision - |